Rutherford-based Cancer Genetics Inc. has received a patent for kidney cancer diagnosis, the sixth leading cancer type among men in the United States.
Granted by the United States Patent and Trademark Office, the patent covers a panel of Cancer Genetics probes that use proprietary methods to detect and differentiate various forms of kidney cancer.
The cancer diagnostics company said its tests address a need to reduce time for initial treatment and establish new non-invasive genomic methods to aid accurate diagnosis.
Cancer Genetics said its methods were validated through studies in collaboration with Memorial Sloan-Kettering Cancer Center and The Cleveland Clinic. The company expects that patent to be issued and a patent number to be assigned by January.
"This most recent patent award for our renal-cancer diagnostic further strengthens our position as we grow our share in this attractive market segment by delivering more value for renal cancer patients and their care providers," Cancer Genetics CEO Panna Sharma said in a statement.